Tumor Ki-67, ER and PR, and antibodies against estradiol and progesterone in breast cancer patients-Reference-Cited by-同舟云学术

Tumor Ki-67, ER and PR, and antibodies against estradiol and progesterone in breast cancer patients

Published:2023-09-29 Issue:3 Volume:8 Page:8-17
ISSN:2542-0941
Container-title:Fundamental and Clinical Medicine
language:
Short-container-title:Fundamentalʹnaâ i kliničeskaâ medicina

Author:

Glushkov A. N.¹^ORCID,Polenok E. G.¹^ORCID,Mun S. A.¹^ORCID,Gordeeva L. A.¹^ORCID,Kostyanko M. V.²^ORCID,Antonov A. V.³^ORCID,Bayramov P. V.³^ORCID,Verzhbitskaya N. E.³^ORCID,Kolpinskiy G. I.⁴^ORCID

Affiliation:

1. Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry, Siberian Branch of the Russian Academy of Sciences

2. Kemerovo State University

3. Kuzbass Clinical Oncological Dispensary

4. Kemerovo State Medical University; Clinical Consulting and Diagnostic Center

Abstract

Aim. To investigate the associations of cell proliferation marker Ki-67 in estrogen receptor (ER) and progesterone receptor (PR) positive (ER+/ PR+) and negative (ER-/PR-) tumors with the ratio of antibodies against estradiol and progesterone (IgA1-E2/IgA1-Pg) in the serum of breast cancer (BC) patients.Materials and Methods. Antibodies against steroid hormones were analyzed by ELISA in the serum of 432 healthy women and 1212 patients with BC (573 patients with I stage and 639 patients with II–IV stages). Expression of Ki-67, ER and PR in tumors was determined by immunohistochemical staining. Serum estradiol and progesterone were measured by enzyme-linked immunosorbent assay.Results. In total, low IgA1-E2/IgA1-Pg (≤ 1) and high IgA1-E2/IgA1-Pg (> 1) ratio were revealed in 49.3% and 50.7% of healthy women; in 25.7% and 74.3% of stage I BC patients with tumor Ki-67 < 14 (р < 0.001; OR = 0.4 and OR = 2.8, respectively), and in 17.1% and 82.9% of stage I BC patients with tumor Ki-67 > 30 (р < 0.001; OR = 0.2 and OR = 4.7, respectively). The differences between patients with low and high tumor Ki-67 levels in relation to low and high IgA1-E2/IgA1-Pg ratio were statistically significant (p = 0.03). In stage I BC patients with ER+/PR+ and tumors with Ki-67 < 14, low and high IgA1-E2/IgA1-Pg ratio were found in 25.0% and 75.0% cases (р < 0.001; OR = 0.3 and OR = 2.9, respectively). In stage I BC patients with ER+/PR+ and tumors with Ki-67 > 30, low and high IgA1-E2/IgA1-Pg ratio were found in 12.9% and 87.1% cases (р < 0.001; OR = 0.2 and OR = 6.6, respectively). In patients with ER+/PR+ tumors, the differences between patients with low and high tumor Ki-67 levels in relation to low and high IgA1-E2/IgA1-Pg ratio were also statistically significant (p = 0.009). In patients with ER-/PR- tumors, the differences between patients with low and high Ki-67 levels in relation to low and high IgA1-E2/IgA1-Pg ratio were not revealed. The proportion of breast cancer patients with tumor Ki-67 > 30 increased from I to II–IV BC stages regardless of IgA1-E2/IgA1-Pg ratio.Conclusion. IgA1-E2/IgA1-Pg ratio may serve as a predictor of tumor proliferative activity in stage I BC patients with ER+/PR+ tumors.

Publisher

Kemerovo State Medical University

Subject

General Medicine

Reference21 articles.

1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. https://doi.org/10.1093/jnci/dju055

2. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808-819. https://doi.org/10.1093/jnci/djaa201

3. Hacking S.M., Wang Y. Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice. J. Clin. Transl. Pathol. 2022;2(2):53-56 https://doi.org/10.14218/jctp.2022.00012

4. Brown J, Scardo S, Method M, Schlauch D, Misch A, Picard S, Hamilton E, Jones S, Burris H, Spigel D. A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States. BMC Cancer. 2022;22(1):502. https://doi.org/10.1186/s12885-022-09557-6

5. Polenok EG, Mun SA, Gordeeva LA, Kostyanko MV, Antonov AV, Verzhbitskaya NE, Kolpinskiy GI, Glushkov AN. Associations of antibodies to benzo[a]pyrene, estradiol and progesterone with estrogen receptor phenotype in breast cancer tissue. Fundamental and Clinical Medicine. 2022;7(1):53-63. (In Russ). https://doi.org/10.23946/2500-0764-2022-7-1-53-63